Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.
- DOI
- 10.1016/j.clml.2026.06.014
- Published
- 2026 Sep
- Container
- Clinical lymphoma, myeloma & leukemia
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clml.2026.06.014,
title = {Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.},
author = {Mina R and Terpos E and Cani L and Nooka A and Trudel S and Voorhees P and Mian H and Dhakal B and Usmani S and Richter J and Popat R and Mateos MV and Lonial S},
year = {2026},
journal = {Clinical lymphoma, myeloma \& leukemia},
doi = {10.1016/j.clml.2026.06.014},
url = {https://doi.org/10.1016/j.clml.2026.06.014}
}RIS
TY - JOUR TI - Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management. AU - Mina R AU - Terpos E AU - Cani L AU - Nooka A AU - Trudel S AU - Voorhees P AU - Mian H AU - Dhakal B AU - Usmani S AU - Richter J AU - Popat R AU - Mateos MV AU - Lonial S PY - 2026 JO - Clinical lymphoma, myeloma & leukemia DO - 10.1016/j.clml.2026.06.014 UR - https://doi.org/10.1016/j.clml.2026.06.014 ER -
APA
R, M., E, T., L, C., A, N., S, T., P, V., H, M., B, D., S, U., J, R., R, P., MV, M., & S, L. (2026). Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.06.014
Source records
- pubmed · retrieved 2026-09-24T20:44:49.083Z